ClinicalTrials.gg
CompletedNCT00921830Updated Oct 6, 2011

Pharmacokinetics of 3 Formulations of Ibuprofen Suppositories

A Phase 1 interventional study of ibuprofen in Healthy, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed at 1 site in Ireland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-06.

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare the pharmacokinetic and bioavailability characteristics of two test formulations of ibuprofen for rectal administration with the profile of a marketed reference formulation of ibuprofen 200 mg (for oral administration).

Read the detailed description

Ibuprofen is a widely used analgesic and antipyretic in adults and children. Two ibuprofen suppository formulations have been developed for pediatric use to facilitate dosing in younger age groups. This is a single-dose, balanced, randomised, three-period crossover study in healthy male and female adult volunteers. Each volunteer will receive a single dose of 50 mg ibuprofen as a suppository, a single dose of 200 mg ibuprofen as a suppository and a single oral dose of 200 mg ibuprofen (tablet). There will be 14 blood samples taken over 12 hours in each study period. Concentrations in plasma of ibuprofen and its S and R enantiomers will be measured using a validated chromatographic method. Standard pharmacokinetic parameters will be obtained and bioavailability on the basis of rate and extent of drug absorption will be assessed.

02

Conditions studied

  • Healthy

Keywords

  • ibuprofen
  • healthy volunteers
  • bioavailability
  • pharmacokinetics
  • suppository
03

In context

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.

First submitted before Johnson & Johnson Consumer and Personal Products Worldwide left Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female volunteers aged between 18 and 55 years
  • \< 27 kg/m2
  • Non-smokers, or smokers of less than 10 cigarettes per day
  • Clinically normal vital signs
  • Clinically normal medical history
  • Clinically normal findings on physical examination
  • Clinically normal findings for haematology and clinical chemistry of blood and urine or showing clinically insignificant deviations only
  • Screening results for drug abuse (taken within 14 days of study start) must be negative for opiates, cannabinoids, amphetamines, methamphetamine, benzodiazepines and cocaine
  • and and C tests, taken within previous 14 days of study start, must be negative
  • Appropriate use of an effective method of (female volunteers only). Use of the oral contraceptive pill is permitted
  • Ability to comprehend and communicate effectively with the Investigator and staff
  • Ability to give written
  • recording (12-lead) within the normal range

Exclusion criteria

Exclusion Criteria:

  • History of peptic ulcer or gastrointestinal bleeding
  • Resting heart rate outside the range 50 - 90 beats per minute or exhibiting any degree of heart block
  • Resting, seated blood pressure less than 100/60 (90/50 for females) or greater than 140/90 mmHg
  • Clinically significant electrolyte imbalance
  • Evidence of clinically significant cardiovascular, haematological, hepatic, gastrointestinal, renal, respiratory, neurological, or psychiatric disease
  • History of medication with any psycho-pharmacologically active agents within the last five years (other than occasional night sedatives)
  • Gastric bleeding or history of allergies to NSAIDs
  • History of psychiatric illness or clinical treatment for psychiatric illness within the last five years
  • History of epilepsy
  • History of significant drug or drug related /intolerance or food allergies
  • Illness within 14 days prior to start of study
  • Hospitalisation within the previous 3 months for major surgery or significant medical illness (at the discretion of the Investigator)
  • Mental handicap as defined by clinical evaluation
  • Tobacco smoking of more than 10 cigarettes per day
  • Participation in a clinical drug study in which blood was taken within 16 weeks prior to the start of the study
  • Donation of blood or plasma within previous 90 days
  • Participation in a clinical trial in the previous 12 months in which a volume of blood exceeding 500 ml was donated
  • Any indication of current or previous abuse of alcohol, solvents or drugs
  • Treatment with a full or regular course of medication during the 28 days prior to the start of the study
  • Use of alcohol on study days or within 24 hours prior to commencement of each study period
  • Intake of grapefruit products within 7 days prior to study commencement
  • Intake of methylxanthine-containing beverages within 24 hours prior to each study period
  • Intake of quantities of methylxanthine or alcohol-containing beverages which, in the opinion of the Investigator are abnormal (habitually taking more than 5 cups or glasses of tea, coffee, cola, chocolate etc per day or habitually taking more than 20g alcohol/day)
  • Taking medication (prescription or proprietary) within 14 days prior to the study start. Paracetamol is allowed up to 72 hours prior to either study period. The oral pill is allowed.
  • Failure to use adequate contraceptive measures; positive pregnancy test (female volunteers only)
  • Lactating/breastfeeding (female volunteers only)
  • Diet, which in the opinion of the Investigator, deviates from a normal diet (e.g. vegans)
  • Not able/not willing to give
  • Not able to be contacted in case of emergency.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Ibuprofen

    ibuprofen

    Drug: ibuprofen

Interventions

  • Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.

    Also known as: MOTRIN®

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters, including AUC0-t and AUC0-∞

    Time frame: 14 samples over 12 hours in each period

Secondary outcomes

  1. Pharmacokinetic parameters, including Cmax, tmax, t1/2 and Terminal Elimination Rate Constant

    Time frame: 14 samples over 12 hours in each period

07

Study locations

1 site
  • Shandon Clinic
    Cork, Co. Cork, Ireland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Jul 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2009
First posted
Jun 16, 2009
Start
Apr 2004
Primary completionActual
Jul 2004
CompletionActual
Nov 2004
Last update
Oct 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00921830
Responsible party
Sponsor
First posted
Jun 16, 2009
Start date
Apr 2004
Primary completion
Jul 2004
Completion
Nov 2004
Last update
Oct 6, 2011

Study contacts

Jerry Cottrell
study director · McNeil UK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion